Serum apolipoprotein B to apolipoprotein A-I ratio predicts mortality in patients with heart failure.
ApoB to ApoA-I ratio
Apolipoprotein
Heart failure
Prognosis
Propensity score matching
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
11 Oct 2023
11 Oct 2023
Historique:
revised:
06
09
2023
received:
22
04
2023
accepted:
15
09
2023
medline:
12
10
2023
pubmed:
12
10
2023
entrez:
12
10
2023
Statut:
aheadofprint
Résumé
Apolipoproteins have been reported to be involved in many cardiovascular diseases. The aim of our study was to investigate the prognostic value of apolipoprotein B (ApoB) to apolipoprotein A-I (ApoA-I) ratio (ApoB/ApoA-I) in patients with heart failure (HF). We randomly assigned 2400 HF patients into the training cohort (n = 1400) and the validation cohort (n = 1000). Using a receiver operating characteristic curve, we identified the optimal cut-off value of the ApoB/ApoA-I in the training cohort as 0.69, which was further validated in the validation cohort. A propensity score matching (PSM) analysis was conducted to eliminate the imbalance in the baseline characteristics of the high and low ApoB/ApoA-I group. A total of 2242 HF patients were generated in the PSM cohort. We also validated our results with an independent cohort (n = 838). Univariate and multivariate analyses were conducted to explore the independent prognostic value of ApoB/ApoA-I in the training cohort (n = 1400), the validation cohort (n = 1000), the PSM cohort (n = 2242), and the independent cohort (n = 838). Patients with high ApoB/ApoA-I ratio had significantly poorer prognosis compared with those with low ApoB/ApoA-I ratio in the training cohort, the validation cohort, the PSM cohort, and the independent cohort (P < 0.05). Multivariate analysis indicated that the ApoB/ApoA-I was an independent prognostic factor for HF in the training cohort [hazard ratio (HR) = 1.637, 95% confidence interval (CI) = 1.201-2.231, P = 0.002], the validation cohort (HR = 1.54, 95% CI = 1.051-2.257, P = 0.027), the PSM cohort (HR = 1.645, 95% CI = 1.273-2.125, P < 0.001), and the independent cohort (HR = 1.987, 95% CI = 1.251-3.155, P = 0.004). Serum ApoB/ApoA-I ratio is an independent predictor for the prognosis of HF patients.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Sichuan Province Key Clinical Specialty Construction Project
Organisme : Panzhihua Science and Technology Bureau
ID : 2020ZD-S-26
Organisme : Sichuan Medical Association Program
ID : S20020
Organisme : Joint Project of Local Universities in Yunnan Province
ID : 202101BA070001-104
Informations de copyright
© 2023 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Sun Q, Jiang S, Wang X, Zhang J, Li Y, Tian J, et al. A prediction model for major adverse cardiovascular events in patients with heart failure based on high-throughput echocardiographic data. Front Cardiovasc Med 2022;9: doi:10.1016/j.jcmg.2020.02.008
Smadja DM. Stem cell therapy, artificial heart or xenotransplantation. What will be new “regenerative” strategies in heart failure during the next decade? Stem Cell Rev Rep 2022;17:1190-1194. doi:10.1111/jth.14462
Edberg SC, Edberg MK. Assay of extracellular proteinases using a colorimetric collagen substrate for the differentiation of Serratia in the tribe Klebsielleae. Med Microbiol Immunol 1985;174:115-118. doi:10.1007/BF02298121
Marsche G, Saemann MD, Heinemann A, Holzer M. Inflammation alters HDL composition and function. Implications for HDL-raising therapies. Pharmacol Ther 2013;137:341-351. doi:10.1016/j.pharmthera.2012.12.001
Gumilas NSA, Harini IM, Ernawati DA, Indriani V, Novrial D, Kurniawan DW. Potential of apolipoprotein A1 (ApoA1) for detecting liver cirrhosis and hepatocellular carcinoma. Asian Pac J Cancer Prev 2022;23:2001-2008. doi:10.31557/APJCP.2022.23.6.2001
Liang R-B, Yu K, Wu J-L, Liu J-X, Lin Q, Li B, et al. Risk factors and their diagnostic values for ocular metastases in invasive ductal carcinoma. Cancer Med 2021;10:824-832. doi:10.1002/cam4.3656
Wang X, Gong Y, Deng T, Zhang L, Liao X, Han C, et al. Diagnostic and prognostic significance of mRNA expressions of apolipoprotein A and C family genes in hepatitis B virus-related hepatocellular carcinoma. J Cell Biochem 2019;120:18246-18265. doi:10.1002/jcb.29131
Button EB, Boyce GK, Wilkinson A, Stukas S, Hayat A, Fan J, et al. ApoA-I deficiency increases cortical amyloid deposition, cerebral amyloid angiopathy, cortical and hippocampal astrogliosis, and amyloid-associated astrocyte reactivity in APP/PS1 mice. Alzheimers Res Ther 2019;11:44. doi:10.1161/JAHA.114.001156
Hughes TA, Calderon RM, Diaz S, Mendez AJ, Goldberg RB. Lipoprotein composition in patients with type 1 diabetes mellitus. Impact of lipases and adipokines. J Diabetes Complications 2016;30:657-668. doi:10.1016/j.jdiacomp.2016.01.018
Cochran BJ, Ong K-L, Manandhar B, Rye K-A. APOA1. A protein with multiple therapeutic functions. Curr Atheroscler Rep 2021;23:11. doi:10.1007/s11883-021-00906-7
Chistiakov DA, Orekhov AN, Bobryshev YV. ApoA1 and ApoA1-specific self-antibodies in cardiovascular disease. Lab Invest 2016;96:708-718. doi:10.1038/labinvest.2016.56
Bhale AS, Venkataraman K. Leveraging knowledge of HDLs major protein ApoA1. Structure, function, mutations, and potential therapeutics. Biomed Pharmacother 2022;154:113634. doi:10.1016/j.biopha.2022.113634
Behbodikhah J, Ahmed S, Elyasi A, Kasselman LJ, de Leon J, Glass AD, et al. Apolipoprotein B and cardiovascular disease: biomarker and potential therapeutic target. Metabolites 2021;11:44-49. doi:10.1016/j.atherosclerosis.2021.05.010
Chen C, Yi W, Zeng Z-F, Wang Q-X, Jiang W, Gao Y-H, et al. Serum apolipoprotein B to apolipoprotein A-I ratio is an independent predictor of liver metastasis from locally advanced rectal cancer in patients receiving neoadjuvant chemoradiotherapy plus surgery. BMC Cancer 2022;22:7. doi:10.2174/1381612825666191126102943
Yang D-D, Chen Z-H, Wang D-S, Yu H-E, Lu J-H, Xu R-H, et al. Prognostic value of the serum apolipoprotein B to apolipoprotein A-I ratio in metastatic colorectal cancer patients. J Cancer 2020;11:1063-1074. doi:10.7150/jca.35659
Robinson GA, Waddington KE, Coelewij L, Peng J, Naja M, Wincup C, et al. Increased apolipoprotein-B:A1 ratio predicts cardiometabolic risk in patients with juvenile onset SLE. EBioMedicine 2021;65:103243. doi:10.1016/j.ebiom.2021.103243
Ivert T, Hammar N, Talbäck M, Malmström H, Leander K, Walldius G. Elevated apolipoprotein B/A-1 ratio is associated with an increased risk of aortic stenosis. Experience from the AMORIS cohort. Heart Lung Circ 2021;30:1050-1057. doi:10.1016/j.hlc.2020.12.005
Song Y, Yang Y, Zhang J, Wang Y, He W, Zhang X, et al. The apoB100/apoAI ratio is independently associated with the severity of coronary heart disease: a cross sectional study in patients undergoing coronary angiography. Lipids Health Dis 2015;14:150-1634.
Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and management of heart failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009;53:e1-e90. doi:10.1016/j.jacc.2008.11.013
Hu Z, Crump SM, Zhang P, Abbott GW. Kcne2 deletion attenuates acute post-ischaemia/reperfusion myocardial infarction. Cardiovasc Res 2016;110:227-237. doi:10.1093/cvr/cvw048
Yap J, Lim FY, Chia SY, Allen JC, Jaufeerally FR, Macdonald MR, et al. Prediction of survival in Asian patients hospitalized with heart failure. Validation of the OPTIMIZE-HF risk score. J Card Fail 2019;25:571-575. doi:10.1016/j.cardfail.2019.02.016
Sartipy U, Dahlström U, Edner M, Lund LH. Predicting survival in heart failure. Validation of the MAGGIC heart failure risk score in 51,043 patients from the Swedish heart failure registry. Eur J Heart Fail 2014;16:173-179. doi:10.1111/ejhf.32
Xanthopoulos A, Tryposkiadis K, Giamouzis G, Konstantinou D, Giannakoulas G, Karvounis H, et al. Larissa heart failure risk score. A proposed simple score for risk stratification in chronic heart failure. Eur J Heart Fail 2018;20:614-616. doi:10.1002/ejhf.1132
Rubin EM, Krauss RM, Spangler EA, Verstuyft JG, Clift SM. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI. Nature 1991;353:265-267. doi:10.1038/353265a0
Moore RE, Navab M, Millar JS, Zimetti F, Hama S, Rothblat GH, et al. Increased atherosclerosis in mice lacking apolipoprotein A-I attributable to both impaired reverse cholesterol transport and increased inflammation. Circ Res 2005;97:763-771. doi:10.1161/01.RES.0000185320.82962.F7
Pan B, Kong J, Jin J, Kong J, He Y, Dong S, et al. A novel anti-inflammatory mechanism of high density lipoprotein through up-regulating annexin A1 in vascular endothelial cells. Biochim Biophys Acta 1861;2016:501-512. doi:10.1016/j.bbalip.2016.03.022
Amin R, Muthuramu I, Aboumsallem JP, Mishra M, Jacobs F, de Geest B. Selective HDL-raising human Apo A-I gene therapy counteracts cardiac hypertrophy, reduces myocardial fibrosis, and improves cardiac function in mice with chronic pressure overload. Int J Mol Sci 2017;18:2012. doi:10.1007/BF01002772
McGrath KC, Li XH, Whitworth PT, Kasz R, Tan JT, McLennan SV, et al. High density lipoproteins improve insulin sensitivity in high-fat diet-fed mice by suppressing hepatic inflammation. J Lipid Res 2014;55:421-430. doi:10.1194/jlr.M043281
Hamid T, Ismahil MA, Bansal SS, Patel B, Goel M, White CR, et al. The apolipoprotein A-I mimetic L-4F attenuates monocyte activation and adverse cardiac remodeling after myocardial infarction. Int J Mol Sci 2020;21:3519. doi:10.1161/CIRCULATIONAHA.109.905471
Cui G, Tian M, Hu S, Wang Y, Wang DW. Identifying functional non-coding variants in APOA5/A4/C3/A1 gene cluster associated with coronary heart disease. J Mol Cell Cardiol 2020;144:54-62. doi:10.1016/j.yjmcc.2020.05.003
Bodde MC, Hermans MPJ, Jukema JW, Schalij MJ, Lijfering WM, Rosendaal FR, et al. Apolipoproteins A1, B, and apoB/apoA1 ratio are associated with first ST-segment elevation myocardial infarction but not with recurrent events during long-term follow-up. Clin Res Cardiol 2019;108:520-538. doi:10.1161/01.CIR.97.18.1837
Iwaoka M, Obata J-e, Abe M, Nakamura T, Kitta Y, Kodama Y, et al. Association of low serum levels of apolipoprotein A-I with adverse outcomes in patients with nonischemic heart failure. J Card Fail 2007;13:247-253. doi:10.1016/j.cardfail.2007.01.007
Abdel-Razek O, Sadananda SN, Li X, Cermakova L, Frohlich J, Brunham LR. Increased prevalence of clinical and subclinical atherosclerosis in patients with damaging mutations in ABCA1 or APOA1. J Clin Lipidol 2018;12:116-121. doi:10.1016/j.jacl.2017.10.010
Haase CL, Frikke-Schmidt R, Nordestgaard BG, Kateifides AK, Kardassis D, Nielsen LB, et al. Mutation in APOA1 predicts increased risk of ischaemic heart disease and total mortality without low HDL cholesterol levels. J Intern Med 2011;270:136-146. doi:10.1111/j.1365-2796.2011.02381.x
Ghodsi S, Mohebi M, Sadre-Bafghi S-A, Poorhosseini H, Salarifar M, Alidoosti M, et al. Prognostic implications of calculated Apo-lipoprotein B in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Outcome is tied to lower cut-points. Clin Cardiol 2021;44:824-832. doi:10.1038/s41598-020-63825-8
Li H, Wang B, Mai Z, Yu S, Zhou Z, Lu H, et al. Paradoxical association between baseline apolipoprotein B and prognosis in coronary artery disease. A 36,460 Chinese cohort study. Front Cardiovasc Med 2022;9:822626. doi:10.1080/07315724.2008.10719718
Hagström E, Steg PG, Szarek M, Bhatt DL, Bittner VA, Danchin N, et al. Apolipoprotein B, residual cardiovascular risk after acute coronary syndrome, and effects of Alirocumab. Circulation 2022;146:657-672. doi:10.1161/CIRCULATIONAHA.121.057807
Xiao J, Ji J, Zhang N, Yang X, Chen K, Chen L, et al. Association of genetically predicted lipid traits and lipid-modifying targets with heart failure. Eur J Prev Cardiol 2023;30:358-366. doi:10.1093/eurjpc/zwac290
Dong J, Yang S, Zhuang Q, Sun J, Wei P, Zhao X, et al. The associations of lipid profiles with cardiovascular diseases and death in a 10-year prospective cohort study. Front Cardiovasc Med 2021;8: doi:10.1016/j.ijcard.2017.12.069
Råmunddal T, Lindbom M, Scharin-Täng M, Stillemark-Billton P, Boren J, Omerovic E. Overexpression of apolipoprotein-B improves cardiac function and increases survival in mice with myocardial infarction. Biochem Biophys Res Commun 2009;385:336-340. doi:10.1016/j.bbrc.2009.05.053
Jun JE, Choi YJ, Lee Y-H, Kim DJ, Park SW, Huh BW, et al. ApoB/ApoA-I ratio is independently associated with carotid atherosclerosis in type 2 diabetes mellitus with well-controlled LDL cholesterol levels. Korean J Intern Med 2018;33:138-147. doi:10.3904/kjim.2017.396
Liu Y, Jia S-d, Yuan D-S, Xu N, Jiang L, Gao Z, et al. Apolipoprotein B/A-I ratio predicts lesion severity and clinical outcomes in diabetic patients with acute coronary syndrome. Circ J 2020;84:1132-1139. doi:10.1253/circj.CJ-19-1097
Holme I, Aastveit AH, Hammar N, Jungner I, Walldius G. Lipoprotein components and risk of congestive heart failure in 84,740 men and women in the Apolipoprotein MOrtality RISk study (AMORIS). Eur J Heart Fail 2009;11:1036-1042. doi:10.1093/eurjhf/hfp129
Florvall G, Basu S, Larsson A. Apolipoprotein A1 is a stronger prognostic marker than are HDL and LDL cholesterol for cardiovascular disease and mortality in elderly men. J Gerontol A Biol Sci Med Sci 2006;61:1262-1266. doi:10.1093/gerona/61.12.1262
Zhou Y, Liu H, Yang H, Zhao X, Jiao Y. The value of the apolipoprotein B/apolipoprotein A1 ratio in predicting the rapid progression of non-culprit coronary lesions in acute coronary syndrome in patients with diabetes mellitus after percutaneous coronary intervention. Int Heart J 2023;64:562, 22-676-569. doi:10.1536/ihj.22-676
Ryoo J-H, Park SK, Hong HP, Kim M-G, Ha CS. Clinical significance of serum apolipoproteins as a predictor of coronary heart disease risk in Korean men. Clin Endocrinol (Oxf) 2016;84:63-71. doi:10.1111/cen.12843
Lu M, Lu Q, Zhang Y, Tian G. ApoB/apoA1 is an effective predictor of coronary heart disease risk in overweight and obesity. J Biomed Res 2011;25:266-273. doi:10.1016/S1674-8301(11)60036-5
Tian M, Li R, Shan Z, Wang DW, Jiang J, Cui G. Comparison of apolipoprotein B/A1 ratio: Framingham risk score and TC/HDL-C for predicting clinical outcomes in patients undergoing percutaneous coronary intervention. Lipids Health Dis 2019;18:202-438. doi:10.1097/MCA.0000000000000100
Liting P, Guoping L, Zhenyue C. Apolipoprotein B/apolipoprotein A1 ratio and non-high-density lipoprotein cholesterol. Predictive value for CHD severity and prognostic utility in CHD patients. Herz 2015;40:1-7. doi:10.1007/s00059-014-4147-5
Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:937-952. doi:10.1016/S0140-6736(04)17018-9
Richart AL, Reddy M, Khalaji M, Natoli AL, Heywood SE, Siebel AL, et al. Apo AI nanoparticles delivered post myocardial infarction moderate inflammation. Circ Res 2020;127:1422-1436. doi:10.1161/CIRCRESAHA.120.316848
Sirniö P, Väyrynen JP, Klintrup K, Mäkelä J, Mäkinen MJ, Karttunen TJ, et al. Decreased serum apolipoprotein A1 levels are associated with poor survival and systemic inflammatory response in colorectal cancer. Sci Rep 2017;7:5374. doi:10.1002/ijc.26435
Yalcinkaya A, Unal S, Oztas Y. Altered HDL particle in sickle cell disease. Decreased cholesterol content is associated with hemolysis, whereas decreased apolipoprotein A1 is linked to inflammation. Lipids Health Dis 2019;18:e0164264. doi:10.1371/journal.pone.0164264
Dong H, Wang J, Hu P, Lu N. Association of apolipoprotein A1, high density lipoprotein cholesterol, and their ratio with inflammatory marker in Chinese adults with coronary artery disease. Angiology 2022; 765-773. doi:10.1177/00033197221121002
Lee JY, Kang MJ, Choi JY, Park JS, Park JK, Lee EY, et al. Apolipoprotein B binds to enolase-1 and aggravates inflammation in rheumatoid arthritis. Ann Rheum Dis 2018;77:1480-1489. doi:10.1136/annrheumdis-2018-213444
Lee Y-B, Choi KM. Diet-modulated lipoprotein metabolism and vascular inflammation evaluated by 18F-fluorodeoxyglucose positron emission tomography. Nutrients 2018;10:1382. doi:10.1016/j.atherosclerosis.2017.04.004
Asciutto G, Wigren M, Fredrikson GN, Mattisson IY, Grönberg C, Alm R, et al. Apolipoprotein B-100 antibody interaction with atherosclerotic plaque inflammation and repair processes. Stroke 2016;47:1140-1143. doi:10.1161/STROKEAHA.116.012677
Torre-Amione G, Kapadia S, Lee J, Durand JB, Bies RD, Young JB, et al. Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart. Circulation 1996;93:704-711. doi:10.1161/01.cir.93.4.704
Edelmann F, Holzendorf V, Wachter R, Nolte K, Schmidt AG, Kraigher-Krainer E, et al. Galectin-3 in patients with heart failure with preserved ejection fraction. Results from the Aldo-DHF trial. Eur J Heart Fail 2015;17:214-223. doi:10.1002/ejhf.203
Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham heart study. Circulation 2003;107:1486-1491. doi:10.1161/01.cir.0000057810.48709.f6
Emoto T, Sawada T, Morimoto N, Tenjin T, Wakimoto T, Ikeda F, et al. The apolipoprotein B/A1 ratio is associated with reactive oxygen metabolites and endothelial dysfunction in statin-treated patients with coronary artery disease. J Atheroscler Thromb 2013;20:623-629. doi:10.5551/jat.16824
Liu Y, Ma X, Ma L, Su Z, Li D, Chen X. Elevated ApoB/ApoA-I ratio is associated with acute anti-N-methyl- d-aspartate receptor encephalitis, but not disease outcomes. Front Neurol 2022;13:896656. doi:10.1182/blood.v97.8.2381
Lin Z, Zhao Y, Xiao L, Qi C, Chen Q, Li Y. Blood urea nitrogen to serum albumin ratio as a new prognostic indicator in critical patients with chronic heart failure. ESC Heart Fail 2022;9:1360-1369. doi:10.1002/ehf2.13825
Durmus E, Kivrak T, Gerin F, Sunbul M, Sari I, Erdogan O. Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio are predictors of heart failure. Arq Bras Cardiol 2015;105:606-613. doi:10.5935/abc.20150126